SUPPORT FOR THE AMENDMENTS

Claim 1 has been amended to clarify the presence of the mineral acid. Claim 1 has also been amended to specify a corticosteroid and an anticholinergic atropine-like compound as optional components. See also Claim 16. See the specification at page 12, lines 8-17 and the paragraph bridging pages 12 and 13. Newly-added Claims 24-27 are also supported by those portions of the specification. The amendment to Claim 18 is also supported by the specification. Accordingly, no new matter is believed to have been added to the application by the amendments submitted above.

7

REMARKS

Claims 1-9, 12-14 and 16-27 are pending upon entry of the amendments above.

At the outset, Applicants wish to thank Examiner Alstrum-Alcevedo for the helpful and courteous discussions held with Applicants' representative on December 3 and December 6, 2010. During those discussions, the Examiner indicated that adding components as optional features of claimed formulation in Claim 1 would be acceptable. The Examiner also indicated that amending Claim 18 as shown above would permit rejoinder of the method claims.

Accordingly, Applicants submit that the present application is now in condition for allowance, and early notification of such action is earnestly solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

Customer Number 22850

Tel: (703) 413-3000 Fax: (703) 413 -2220 James J. Kelly, Ph.D. Attorney of Record Registration No. 41,504